ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ and Miroslav PENKA. Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms. Neoplasma. Bratislava: Slovenská akademie vied, 2021, vol. 68, No 6, p. 1341-1350. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2021_210729N1068.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms
Authors ASWAD, Mohamed Hussam (760 Syrian Arab Republic, guarantor, belonging to the institution), Jarmila KISSOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution).
Edition Neoplasma, Bratislava, Slovenská akademie vied, 2021, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.409
RIV identification code RIV/00216224:14110/21:00122606
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4149/neo_2021_210729N1068
UT WoS 000729198300012
Keywords in English Myeloproliferative neoplasm; Thrombosis; Risk factor; JAK2V617F mutation; Smoking
Tags 14110212, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 10:49.
Abstract
Thrombosis is the most common complication in BCR-ABL1 negative myeloproliferative neoplasms (MPN) that significantly impacts patients’ mortality. Generally, there is an agreement on risk factors that possibly contribute to the increased risk of thrombosis, including age, history of thrombosis, JAK2V617F mutation, and cardiovascular risk factors. This study retrospectively investigates MPN-related and patient-related variables in relation to the thrombosis occurrence in MPN. Our analyses show that JAK2V617F-mutated patients are at a significantly increased risk of thrombosis within five years before the MPN diagnosis point with a hazard ratio (HR) of 15.49 (P = 0.006). In multivariate analyses, independent risk factors for thrombotic complications during the follow-up are history of thrombosis (HR = 2.23, P = 0.019), age over 60 years at diagnosis (HR = 1.56, P = 0.037), the presence of JAK2V617F mutation (HR = 3.01, P = 0.002), and tobacco smoking (HR = 1.75, P = 0.01). Our results support the multifactorial mechanism of thrombosis in MPN patients, which demands individual and complex management.
PrintDisplayed: 4/5/2024 12:48